Rheumatology Research Review, Issue 87

In this issue:

The overall risk of cancer with TNFi, tocilizumab, abatacept, or rituximab
Higher B-cell infiltration in ACPA+ RA patients
Biosimilar Brenzys: comparable efficacy, safety to reference entanercept
Effects of febuxostat in early gout
Survival trends since 1950 in adults & children with SLE
Optimal vs non-optimal methotrexate dose: clinical outcomes
Tocilizumab treats checkpoint inhibitor-induced arthritis
Allopurinol: a treat-to-target approach works well in gout
Haemophilia B gene therapy looks very promising
Selexipag disappoints in Raynaud’s phenomenon

Please login below to download this issue (PDF)

Subscribe